glp 1 for non obese What is the pipeline future medications for obesity? GLP-1 for Weight Loss and

Given the intractable pediatric obesity epidemic and associated rise in type 2 diabetes in youth, made worse by the COVID-19 pandemic related shutdowns and disruptions in opportunities for exercise and play in youth, this new class of medications will certainly benefit children with morbid obesity and type 2 diabetes

GLP-1RAs improve risk factors for CV disease, including weight loss, blood glucose control, blood pressure reduction, and lipid improvement

Out-of-pocket costs for GLP-1 medications are substantial without insurance coverage

The goal remains evidence-informed care that prioritises patient safety and optimises outcomes

Why this matters: Since compounded products may vary in quality, potency, and dosing, they are not interchangeable with FDA-approved medications

NN9068-3697 (DUAL-I) trial investigators